

# Prescription Monitoring Program Advisory Council State of Louisiana

July 08, 2020

## MINUTES

A meeting of the Louisiana Prescription Monitoring Program (PMP) Advisory Council scheduled to meet on Wednesday, July 8, 2020, by Videoconference convened at 1:00 p.m. to consider the following:

### **A G E N D A**

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items & Adoption of Agenda
4. Consideration of Minutes from Prior Meeting – January 8, 2020
5. Opportunity for Public Comment
6. Annual Election of Council Officers
7. Review of Program Operation
8. Regulatory Update
9. Calendar Notes
10. Adjourn

**Advisory Council Representatives/Designees present:** Carl Aron (LABP) chaired the meeting. Also present were Roger Hamilton (LaSenPres), Mary Peyton (LSBME), Lauren Bailey (LSMS), Beverly Walker (LPA), Bud Courson (LAMP), Lawrence Alexander, Jr. (DEA), Lt. Brit Forbes (LSP), Charles Cravins (LDAA), Mary Staples (NACDS), Bryanna Clark (PhRMA), and Russell Caffery (LIPA).

**Others present:** Malcolm Broussard, Joe Fontenot, Carlos Finalet, Danielle Hartzog, Nerissa Montgomery, Reshmi Ravindranath, and Kelly Villeneuve (all LABP). Ben Sims, Crystal Carter, Dr. Joseph Comaty, Johnny Staub, Paula Belle, and T.J. Woodard

### **Call for Additional Agenda Items & Adoption of Agenda**

No additional agenda items introduced, agenda adopted.

### **Consideration of Minutes from the January 08, 2020 Meeting**

Minutes were approved by consensus with no corrections.

### **Opportunity for Public Comment**

No public comments.

### **Election of Council Officers**

The only nomination for the office of Chair was Carl Aron (LABP). Mr. Aron was elected by acclamation and assumed the office immediately.

The only nomination for the office of Vice Chair was Hon. Charles T. Cravins. Hon. Charles T. Cravins was elected by acclamation and assumed the office immediately.

### **Review of Program Operation**

Joe Fontenot, Assistant Executive Director, presented statistical information regarding the program to the council. (**Attachment 1**). Furthermore, Mr. Fontenot provided an update on the statewide PMP integration project, letting the council know that as of July 1, 2020 the PMP is interoperable with more than 1,600 facilities across the state.

### **Interstate Data Sharing through PMP Interconnect**

Mr. Fontenot informed the council that the Louisiana PMP is currently sharing PMP information with 31 other state PMPs and the U.S. Department of Defense (DOD) through the NABP PMP InterConnect (PMPi). (Alabama, Alaska, Arizona, Arkansas, Connecticut, Delaware, D.C., Florida, Georgia, Idaho, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nevada, New Mexico, North Carolina, North Dakota, Oklahoma, Pennsylvania, Puerto Rico, South Carolina, South Dakota, Tennessee, Texas, Virginia and West Virginia)

RxCheck Interstate Data Sharing Hub

Mr. Fontenot reminded the PMP Advisory Council of previous discussions regarding the RxCheck Interstate Data Sharing Hub. He informed the council the connection was complete on April 17, 2020 and the connection will be maintained until such time as the requirements of the grant no longer necessitate a connection.

Pharmacy Audits

Mr. Fontenot explained to the council that monitoring pharmacy compliance in regards to the PMP reporting requirements is a priority for PMP staff. In addition to making sure each pharmacy reports each day they are open for business, the Board of Pharmacy Compliance Officers are performing random on-site audits to ensure pharmacies are reporting all of their eligible prescription transactions. For non-resident pharmacies, the audit process involves issuing subpoenas for the pharmacy's prescription logs which are then compared with the pharmacy's PMP reports.

Violations – Mr. Fontenot mentioned from time to time, PMP staff encounters pharmacy permits who choose not to comply with the reporting requirements of the PMP and the disciplinary actions taken by the Board against those pharmacies have been reported to the Advisory Council. In March of this year, the Violations Committee of the Board was scheduled to address two pharmacy permits and their pharmacists-in charge for failure to correct or amend erroneous data in the PMP. In both cases, the pharmacy's reported PMP data but the data contained errors which prevented the information from being entered into the database. After numerous attempts by PMP staff to address the issue, the pharmacies were referred to the committee. He informed the council that the March meeting had to be postponed due to COVID-19 and has been rescheduled for July 14-15, 2020. Once these matters are concluded, he will update the council of the outcomes.

Regulatory Update

Mr. Malcolm Broussard reviewed Regulatory Project 2020-1 ~ Prescription Monitoring Program and noted the proposed revisions to the original proposed rule. (**Attachment 2**)

Calendar Notes

The remaining meeting date in 2020 is: October 8.

Adjournment

With no business remaining, the Council adjourned at 1:40 p.m.

*I certify that the foregoing are true and accurate minutes.*

---

Malcolm J. Broussard  
Executive Director  
Louisiana Board of Pharmacy


*Prepared by: Danielle Hartzog, Administrative Assistant, Louisiana Board of Pharmacy*

 **LOUISIANA  
BOARD of  
PHARMACY**

**PRESCRIPTION MONITORING  
PROGRAM (PMP)**


ADVISORY COUNCIL MEETING – JULY 8, 2020

1



# PMP Reporting Comparisons

## Reporting through 06/30/2020



5

### PMP User Stats 2020.Q2 (April 1, 2020 through June 30, 2020 (COVID-19))


Healthcare Provider Role	Number of Providers Eligible for PMP Access (as of 06/30/2020)	Number of Providers with PMP Active Access Privileges (as of 06/30/2020)	Number of PMP Requests by Providers through AWAARxE® During 2020.Q2	Number of PMP Requests by Providers through Gateway® During 2020.Q2
Physician (MD, DO)	13,425	8,798	403,406	2,368,679
Nurse Practitioner (APRN)	3,880	2,997	137,058	331,578
Dentist (DDS)	2,327	1,551	4,489	388
Physician Assistant (PA)	1,030	766	19,460	32,194
Optometrist (OD)	363	153	5	0
Podiatrist (DPM)	167	109	619	0
Medical Psychologist (MP)	93	86	7,090	3,302
Medical Intern/Resident	1,211	1,145	6,163	1,415
Prescriber's Delegate	NA	2,851	185,906	0
Pharmacist (PST)	9,147	4,448	690,478	1,513,016
Pharmacist's Delegate	NA	1,171	60,637	0
<b>Totals</b>	<b>31,643</b>	<b>24,075</b>	<b>1,515,311</b>	<b>4,250,572</b>

### PMP User Stats 2020.Q1 (January 1, 2020 through March 31, 2020 (Covid-19))

Healthcare Provider Role	Number of Providers Eligible for PMP Access (as of 04/30/2020)	Number of Providers with PMP Active Access Privileges (as of 04/30/2020)	Number of PMP Requests by Providers through AWAARxE® During 2020.Q1	Number of PMP Requests by Providers through Gateway® During 2020.Q1
Physician (MD, DO)	13,256	8,787	432,010	2,909,780
Nurse Practitioner (APRN)	3,816	2,962	125,520	411,263
Dentist (DDS)	2,272	1,552	5,694	634
Physician Assistant (PA)	1,014	765	22,884	50,595
Optometrist (OD)	359	154	10	0
Podiatrist (DPM)	164	110	481	0
Medical Psychologist (MP)	93	86	6,613	0
Medical Intern/Resident	1,206	1,128	6,122	0
Prescriber's Delegate	NA	2,790	207,340	0
Pharmacist (PST)	9,098	4,411	529,249	1,685,883
Pharmacist's Delegate	NA	1,116	52,975	0
<b>Totals</b>	<b>31,278</b>	<b>23,861</b>	<b>1,388,898</b>	<b>5,058,155</b>

## Louisiana Prescriber & Pharmacist Searches through AWARxE and Gateway


(Ending 06/30/2020)



4

## PMP Statewide Integration Project

As of July 1, 2020, the Louisiana PMP is interoperable with **176 licensees** (EHRs and pharmacy management systems) across the state. The **176 licensees** represent more than **1,600 facilities** in Louisiana and are responsible for **1,810,207 PMP requests** in the month of June.



**GATEWAY REQUESTS BREAKDOWN**

Monitor Gateway requests from Licensees, Facilities, Requesters, and Patients Searched.

A Gateway request includes all incoming transactions generated by an end user through an integrated system. Specifically, it includes all 1st Single calls as well as any 2nd calls for ADIs that allow them. It doesn't include outgoing requests to PMP InterConnect.

Request Successful: (All) | Request Type: (Multiple values) | Licensee: (All) | Year: 2020 | Month: 6

Total Requests: **1,810,207**

Requests by Licensee (Show Top 10 Licensees 300)

Rank	Licensee	Licensee Address	State Code	Zip	Requests (K)
Grand Total					1,810,207
1	Optimer Health System	1514 Jefferson Hwy	LA	70121	335,372
2	Athena Health	321 Arsenal Street	MA	02472	278,589
3	Waggreen's Pharmacy	200 Wilcox	IL	60015	276,008
4	Franciscan Missionaries of La.	5999 S. Sherwood Forest Blvd	LA	70156	252,208
5	Louisiana Children's Medical	200 Henry Clay Ave.	LA	70118	145,279
6	CVS Health - NordCare Report	1 CVS Drive	RI	02899	122,256
7	Walmart Pharmacy	702 SW 8th Street	AR	72716	86,613
8	Lafayette General Hospital	920 W. Pinhook Rd	LA	70503	58,111
9	CHRISTUS Health(TX)Statew.	928 Hidden Ridge	TX	75038	55,466
10	North Oaks Health Systems	15790 Paul Vega HO Drive	LA	70420	52,456

# NABP PMP InterConnect®

## PMP Interstate Data Sharing

As of June 30, 2020, the Louisiana PMP is sharing with 31 states and the U.S. Military Health System (MHS) – Department of Defense (DOD)

Alabama	Kansas	North Dakota
Alaska	Maine	Oklahoma
Arizona	Massachusetts	Pennsylvania
Arkansas	Michigan	Puerto Rico
Connecticut	Minnesota	South Carolina
Delaware	Mississippi	South Dakota
D.C.	Montana	Tennessee
Florida	Nevada	Texas
Georgia	New Mexico	Virginia
Idaho	North Carolina	West Virginia
Iowa		

13

## Law Enforcement Requests

Requests through 06/30/2020



14

# Drugs of Concern

*Drugs of Concern*—drugs other than controlled substances as defined by rule whose use requires tracking for public health purposes or which demonstrate a potential for abuse, including any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, esters, ethers, isomers, and salts of isomers [whenever the existence of such salts, esters, ethers, isomers, and salts of isomers is possible within the specific chemical designation]:

- a. butalbital when in combination with at least 325 milligrams of acetaminophen per dosage unit.
- b. naloxone.
- c. promethazine when present in oral liquid formulation.
- d. elbasvir / grazoprevir.
- e. glecaprevir / pibrentasvir.
- f. ledipasvir / sofosbuvir.
- g. ombitasvir / paretaprevir / ritonavir / dasabuvir.
- h. sofosbuvir.
- i. sofosbuvir / velpatasvir.
- j. sofosbuvir / velpatasvir / voxilaprevir.
- k. gabapentin.

# Additional Updates

- **RxCheck® Interstate Data Sharing Hub** – Connected on April 17, 2020
  - Part of a “Special Condition” in order for LDH-OPH-BCP to receive federal CDC grant money.
- **Pharmacy Audits** – Part of Compliance Reviews
  - On-Site Pharmacy Audits
  - Subpoena Audits
- **Violations** – Cases against 2 pharmacies and their PICs scheduled for July 14-15, 2020.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
 Baton Rouge, Louisiana 70809-1700  
 Telephone 225.925.6496 ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## MEMORANDUM

To: PMP Advisory Council

From: Malcolm Broussard

Date: July 8, 2020

Re: Agenda Item 8 ~ Regulatory Update

---

As was reported during the previous meeting in January, the Board initiated the rulemaking process to substantially revised the current chapter of rules for the prescription monitoring program. We published the Notice of Intent in the April 2020 edition of the state register and conducted the public hearing on May 29. During their subsequent meeting on June 25, the Board evaluated the comments and testimony received at the public hearing and voted to revise the original proposal in one place.

The original proposal amended the definition of “drugs of concern” by adding 9 new drugs to the 2 drugs in the current definition. The 9 new drugs consist of the 2 new drugs requested by the PMP Advisory Council (promethazine when present in oral liquid formulations as well as gabapentin) as well as 7 new drugs used to cure hepatitis requested by the Dept. of Health. During their June 25 meeting, the members voted to remove the 7 new drugs used for hepatitis and keep the other 2 drugs, promethazine and gabapentin. We anticipate publishing those proposed revisions in the July 2020 issue of the state register and conducting a second public hearing on those proposed revisions on August 26. The Board will evaluate the comments and testimony from that public hearing and determine a path forward. Given the multiple variables in the rulemaking process, we are not able to predict when the final rule will take effect but we are hopeful for an effective date in the last quarter of this calendar year.

---

**NOTICE:** In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

**NOTICE:** In compliance with Act 655 of the 2018 Louisiana Legislature, the Board gives notice to its licensees and applicants of their opportunity to file a complaint about the Board’s actions or procedures. You may submit such complaints to one or more of the following: (1) Louisiana Board of Pharmacy; 3388 Brentwood Dr., Baton Rouge, La 70809; 225.925.6496; [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov) (2) Committee on House & Governmental Affairs; La. House of Representatives; PO Box 44486; Baton Rouge, LA 70804; 225.342.2403; [h&ga@legis.la.gov](mailto:h&ga@legis.la.gov) (3) Committee on Senate & Governmental Affairs; La. Senate; PO Box 94183; Baton Rouge, LA 70804; 225.342.9845; [s&g@legis.la.gov](mailto:s&g@legis.la.gov)